Does Metoprolol Cause Hair Loss?

How Metoprolol Is Linked to Hair Loss

Metoprolol belongs to the beta-adrenergic receptor blocker class, one of the most widely prescribed drug families in cardiology. It works by blocking beta-1 receptors in the heart, reducing heart rate and cardiac output. Hair loss is not among the reasons most patients take this drug, but it appears in post-marketing adverse event databases and case reports as an uncommon but real side effect.

The FDA Label and Post-Marketing Reports

The FDA-approved prescribing information for metoprolol succinate lists alopecia under dermatologic adverse reactions observed during post-marketing experience [1]. A 2021 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that beta-blockers as a class generated a disproportionately high signal for alopecia reports, with metoprolol among the most frequently implicated agents [2]. The analysis identified over 3,800 alopecia reports linked to beta-blockers between 2004 and 2020.

Incidence in Clinical Trials

Large randomized trials of metoprolol, such as MERIT-HF (N=3,991), did not systematically track hair-related endpoints [3]. Most incidence estimates come from post-marketing surveillance rather than prospective trial data. The prescribing label classifies alopecia as "uncommon," a regulatory term corresponding to an incidence of 0.1% to 1%. Real-world pharmacovigilance databases suggest the true rate may approach 2% to 5% when patients are asked directly, because hair thinning is underreported when not specifically queried [2].

Why Beta-Blockers Cause Hair Shedding

The mechanism connecting beta-blockers to hair loss is not fully mapped, but the prevailing explanation centers on disruption of the hair follicle growth cycle. Understanding this helps distinguish drug-induced shedding from other causes.

The Telogen Effluvium Pathway

Hair follicles cycle through three phases: anagen (active growth, lasting 2 to 7 years), catagen (regression, about 2 weeks), and telogen (resting, about 3 months). A 2019 review in the Journal of the American Academy of Dermatology described how certain medications prematurely shift anagen follicles into telogen, producing diffuse shedding 2 to 4 months after the trigger begins [4]. Beta-blockers are thought to do this by reducing peripheral blood flow to the dermal papilla and by modulating catecholamine signaling that supports anagen maintenance.

Beta-1 vs. Non-Selective Blockers

Metoprolol is beta-1 selective, meaning it preferentially targets cardiac receptors over the beta-2 receptors found in smooth muscle and skin vasculature. Non-selective beta-blockers like propranolol theoretically carry a higher risk of hair-related side effects because they also block beta-2 receptors in the skin. A 2002 case series published in the British Journal of Dermatology reported telogen effluvium in patients on propranolol, nadolol, and metoprolol, but noted that selective agents produced fewer and milder cases [5].

Dr. Wilma Bergfeld, a dermatologist at the Cleveland Clinic who has published extensively on drug-induced alopecia, stated in a 2020 interview: "Beta-blockers are a well-recognized cause of telogen effluvium. The good news is that the hair loss is almost universally reversible once the offending agent is removed or replaced."

The Role of Dose and Duration

Higher doses appear more likely to cause shedding. Patients on metoprolol succinate 200 mg daily report hair thinning more frequently than those on 25 mg or 50 mg, based on FAERS signal-to-noise ratios [2]. Duration also matters. Some patients notice shedding only after months of stable dosing, suggesting a cumulative shift of follicles into telogen rather than an acute toxic event.

Recognizing Drug-Induced Hair Loss vs. Other Causes

Not every patient who takes metoprolol and notices hair thinning can attribute it to the drug. Several other conditions cause similar patterns, and accurate diagnosis changes management.

Telogen Effluvium Characteristics

Drug-induced telogen effluvium produces diffuse thinning across the entire scalp rather than the receding hairline or crown thinning of androgenetic alopecia. A 2016 study in the International Journal of Trichology noted that telogen effluvium accounts for roughly 30% of all alopecia cases evaluated in dermatology clinics [6]. The hallmark is a positive "hair pull test," where gentle traction on a cluster of 40 to 60 hairs yields more than 6 telogen (club-shaped root) hairs.

Ruling Out Competing Diagnoses

Thyroid dysfunction, iron deficiency, and androgenetic alopecia are the three most common mimics. The American Academy of Dermatology guidelines recommend checking TSH, ferritin, and CBC in any patient presenting with new-onset diffuse shedding [7]. If metoprolol is suspected, timing is the strongest diagnostic clue. Onset 8 to 16 weeks after starting the drug, with no other identifiable trigger, supports a causal link.

When Stress Confounds the Picture

Many patients start metoprolol after a cardiac event. Heart attacks, surgeries, and hospitalizations are themselves potent triggers of telogen effluvium through physiologic stress. A 2017 review in the Journal of Clinical and Diagnostic Research found that 30% to 40% of patients admitted to ICUs developed telogen effluvium within 3 months of discharge, regardless of medications [8]. Distinguishing drug-induced shedding from stress-induced shedding in post-MI patients is genuinely difficult and often requires a trial discontinuation or drug switch.

What to Do If You Suspect Metoprolol Is Causing Hair Loss

The most important instruction: do not stop metoprolol on your own. Abrupt withdrawal of beta-blockers can trigger rebound tachycardia, hypertensive crisis, or worsening angina. The 2017 ACC/AHA hypertension guidelines recommend tapering beta-blockers over 1 to 2 weeks under physician supervision [9].

Step 1: Document the Timeline

Write down when you started metoprolol (or changed the dose) and when shedding began. Photograph the scalp under consistent lighting every 2 weeks. This timeline is the single most useful piece of information your clinician needs.

Step 2: Request Baseline Labs

Ask for TSH, free T4, ferritin, iron saturation, and a complete blood count. These rule out thyroid disease and iron deficiency, the two most treatable non-drug causes of telogen effluvium. A ferritin level below 30 ng/mL is associated with increased shedding risk even in the absence of frank anemia [7].

Step 3: Discuss a Supervised Switch

If labs are normal and the timeline implicates metoprolol, your prescriber may trial a different antihypertensive class altogether (an ACE inhibitor, ARB, or calcium channel blocker) or switch to a beta-blocker with fewer reported alopecia signals. Nebivolol, a third-generation beta-1 selective blocker with nitric oxide-mediated vasodilation, has generated fewer alopecia reports per prescription in FAERS data [2].

The European Society of Cardiology 2024 hypertension guidelines state: "When adverse effects affect quality of life, switching within or between drug classes is preferred over treatment discontinuation, provided the cardiovascular indication remains managed" [10].

Step 4: Allow Time for Recovery

After removing the suspected trigger, telogen effluvium typically resolves in 3 to 6 months. The shedding may briefly worsen in the first 2 to 4 weeks after a switch because follicles already committed to telogen will complete the cycle. This "extinction burst" is normal and should not prompt further medication changes.

Do Both Metoprolol Formulations Carry the Same Risk?

Metoprolol tartrate (immediate-release, dosed twice daily) and metoprolol succinate (extended-release, dosed once daily) share the same active molecule. They differ only in release kinetics.

Pharmacokinetic Considerations

Metoprolol tartrate produces higher peak plasma concentrations (Cmax) but shorter duration, while succinate provides a flatter curve over 24 hours. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics showed that peak metoprolol concentrations with tartrate 50 mg BID were approximately 40% higher than with succinate 100 mg QD at steady state [11]. Whether these peak-trough differences matter for hair follicle toxicity is unknown, and no head-to-head comparison has been conducted specifically for alopecia risk.

What FAERS Data Suggest

Both formulations generate alopecia signals in the FAERS database. The absolute number of reports is higher for metoprolol succinate, but this likely reflects its larger market share rather than a true difference in risk. No published analysis has demonstrated a statistically significant difference in alopecia incidence between the two formulations.

Other Cardiovascular Drugs That Can Cause Hair Loss

Metoprolol is not the only cardiac medication associated with hair thinning. Patients on combination regimens may face additive risk, making the source harder to isolate.

Anticoagulants

Heparin and warfarin are both documented causes of telogen effluvium. A 2018 retrospective cohort published in Thrombosis Research reported hair loss in 3.2% of patients on warfarin at 6 months [12]. Direct oral anticoagulants (apixaban, rivaroxaban) appear to carry a lower risk, though post-marketing reports exist for both.

ACE Inhibitors and Statins

Lisinopril, enalapril, and captopril have sporadic alopecia case reports but no strong pharmacovigilance signal. Statins, particularly atorvastatin and simvastatin, generate a modest signal in FAERS, though the incidence is estimated below 1% in most analyses [13]. If a patient on metoprolol plus atorvastatin reports shedding, distinguishing the culprit requires sequential withdrawal or substitution.

Calcium Channel Blockers

Amlodipine and other dihydropyridine CCBs are occasionally implicated but with weaker evidence than beta-blockers. CCBs may actually be a reasonable switch target for patients with metoprolol-associated alopecia who still need antihypertensive therapy.

Supportive Measures During Recovery

While waiting for hair to regrow after a drug switch, several evidence-based interventions can support the process.

Nutritional Optimization

Iron and vitamin D deficiency accelerate telogen effluvium. A 2013 study in the Journal of Korean Medical Science found that women with ferritin levels <30 ng/mL had significantly more telogen hair loss than those with levels above 70 ng/mL [14]. Supplementing to a ferritin target of 50 to 70 ng/mL is a reasonable goal when baseline levels are low.

Topical Minoxidil

Topical minoxidil 5% is FDA-approved for androgenetic alopecia, not telogen effluvium. A 2014 open-label trial (N=36) showed faster recovery of hair density in telogen effluvium patients using minoxidil compared to observation alone [15]. The effect was modest, roughly 6 to 8 weeks faster regrowth, and minoxidil can cause its own brief shedding phase in the first 2 to 4 weeks.

What Not to Do

Avoid biotin megadoses (over 5 mg/day) without documented deficiency. High-dose biotin interferes with troponin and thyroid immunoassays, a serious concern in patients on cardiac medications who may need serial troponin testing. The FDA issued a safety communication about this in 2017 [16].